What does Ultragenyx Pharmaceutical, Inc. do?

Jun 22 2025 06:34 PM IST
share
Share Via
Ultragenyx Pharmaceutical, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for genetic diseases. As of March 2025, it reported net sales of $139 million and a net loss of $151 million, with a market cap of approximately $3.47 billion.
Overview:
Ultragenyx Pharmaceutical, Inc. is a clinical-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company. Financial Snapshot: Most recent Net Sales: 139 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -151 Million (Quarterly Results - Mar 2025) Market-cap: USD 3,465.91 Million (Small Cap) Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 2.49 Return on Equity: -377.52% Price to Book: 24.03 Contact Details: Address: 60 Leveroni Ct, NOVATO CA: 94949-5746 Tel: 1 415 4838800 Fax: 1 415 4838810 Website: https://www.ultragenyx.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News